Stockscreener 앱 받기
4.66
4.48%
0.20
시장 영업 전:
4.60
-0.06
-1.29%
전일 마감가:
$4.46
열려 있는:
$4.5
하루 거래량:
2.41M
Relative Volume:
1.10
시가총액:
$780.00M
수익:
$25.55M
순이익/손실:
$-341.97M
주가수익비율:
-1.6643
EPS:
-2.8
순현금흐름:
$-304.44M
1주 성능:
+7.25%
1개월 성능:
+12.02%
6개월 성능:
-45.81%
1년 성능:
-54.22%
1일 변동 폭
$4.35
$4.67
1주일 범위
$3.50
$4.67
52주 변동 폭
$3.50
$11.16
릴레이 테라퓨틱스 Stock (RLAY) Company Profile
명칭
Relay Therapeutics Inc
전화
617-370-8837
주소
399 BINNEY STREET, CAMBRIDGE
RLAY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RLAY
Relay Therapeutics Inc
|
4.66 | 780.00M | 25.55M | -341.97M | -304.44M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
릴레이 테라퓨틱스 Stock (RLAY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-09-10 | 재개 | Goldman | Buy |
| 2024-09-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-09-10 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-05-10 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2023-04-20 | 업그레이드 | Jefferies | Underperform → Hold |
| 2023-04-19 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-04-13 | 개시 | Raymond James | Outperform |
| 2023-02-03 | 개시 | Oppenheimer | Outperform |
| 2022-09-30 | 개시 | Barclays | Equal Weight |
| 2022-09-02 | 개시 | Stifel | Buy |
| 2022-06-06 | 개시 | Jefferies | Underperform |
| 2022-02-01 | 개시 | Berenberg | Buy |
| 2021-07-21 | 개시 | BofA Securities | Buy |
| 2020-12-15 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-08 | 개시 | JMP Securities | Mkt Outperform |
| 2020-11-05 | 개시 | H.C. Wainwright | Buy |
| 2020-08-10 | 개시 | Cowen | Outperform |
| 2020-08-10 | 개시 | Goldman | Buy |
| 2020-08-10 | 개시 | Guggenheim | Buy |
| 2020-08-10 | 개시 | JP Morgan | Neutral |
모두보기
릴레이 테라퓨틱스 주식(RLAY)의 최신 뉴스
Relay Therapeutics (NASDAQ:RLAY) Sets New 52-Week LowShould You Sell? - MarketBeat
Relay Therapeutics, Inc. (NASDAQ:RLAY) Short Interest Update - MarketBeat
Relay Therapeutics' SWOT analysis: stock poised for growth amid fierce competition - MSN
Relay Therapeutics (NASDAQ:RLAY) Stock Price Down 4.8%Time to Sell? - MarketBeat
We're Keeping An Eye On Relay Therapeutics' (NASDAQ:RLAY) Cash Burn Rate - Yahoo Finance
Relay Therapeutics’ (RLAY) Buy Rating Reiterated at HC Wainwright - Defense World
Layoff Tracker: Notch Therapeutics to ‘Significantly Reduce’ Workforce - BioSpace
Relay Therapeutics (NASDAQ:RLAY) Hits New 52-Week LowShould You Sell? - MarketBeat
Relay Therapeutics (NASDAQ:RLAY) Given "Buy" Rating at HC Wainwright - MarketBeat
Relay Therapeutics Highlights Progress at Healthcare Conference - TipRanks
Barclays PLC Grows Stake in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Barclays PLC Purchases 136,541 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - MarketBeat
Eli Lilly in talks to acquire Scorpion Therapeutics, FT says; Relay Therapeutics seesaws - MSN
Relay Therapeutics, Inc. (NASDAQ:RLAY) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Relay Therapeutics stock hits 52-week low at $4 By Investing.com - Investing.com South Africa
Relay Therapeutics (NASDAQ:RLAY) Hits New 12-Month LowShould You Sell? - MarketBeat
Relay Therapeutics stock hits 52-week low at $4 - Investing.com India
Eli Lilly in talks to acquire Scorpion Therapeutics, FT says; Relay Therapeutics seesaws (LLY:NYSE) - Seeking Alpha
Relay Therapeutics Chief Corporate Development Officer Peter Rahmer Sells 63% Of Holding - Simply Wall St
Relay Therapeutics (NASDAQ:RLAY) Stock Price Up 4.8%Should You Buy? - MarketBeat
Relay Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Relay Therapeutics officer sells shares worth $345,571 By Investing.com - Investing.com Australia
Relay Therapeutics, Inc. (NASDAQ:RLAY) Insider Sells $73,763.20 in Stock - MarketBeat
Relay Therapeutics, Inc. (NASDAQ:RLAY) Insider Peter Rahmer Sells 32,156 Shares - MarketBeat
Relay Therapeutics officer sells shares worth $345,571 - Investing.com India
Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares Bought by JPMorgan Chase & Co. - Defense World
JPMorgan Chase & Co. Grows Stock Holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY) - MarketBeat
Relay Therapeutics' chief corporate development officer sells $1,752 in stock - Investing.com India
Relay Therapeutics stock hits 52-week low at $4.11 amid market challenges - Investing.com Australia
Relay Therapeutics president sells shares for $2,877 By Investing.com - Investing.com Australia
Relay Therapeutics’ chief corporate development officer sells $1,752 in stock By Investing.com - Investing.com Nigeria
Relay Therapeutics' chief corporate development officer sells $1,752 in stock By Investing.com - Investing.com Australia
Relay Therapeutics president sells shares for $2,877 - Investing.com India
Relay Therapeutics chief legal officer sells $1,309 in stock By Investing.com - Investing.com Nigeria
Relay Therapeutics chief legal officer sells $1,309 in stock - Investing.com India
Thomas Catinazzo Sells 4,865 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) Stock - MarketBeat
Relay Therapeutics CFO sells $21,490 in stock By Investing.com - Investing.com Nigeria
Relay Therapeutics CFO sells $21,490 in stock - Investing.com
릴레이 테라퓨틱스 (RLAY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
릴레이 테라퓨틱스 주식 (RLAY) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Rahmer Peter | See remarks |
Jan 03 '25 |
Sale |
4.30 |
32,177 |
138,361 |
325,330 |
| Rahmer Peter | See remarks |
Jan 02 '25 |
Sale |
4.15 |
32,156 |
133,447 |
357,507 |
| Rahmer Peter | See remarks |
Jan 06 '25 |
Sale |
4.45 |
16,576 |
73,763 |
308,754 |
4.81%
자본화:
|
볼륨(24시간):